Switching from salmeterol/fluticasone to formoterol/budesonide combinations improves peripheral airway/alveolar inflammation in asthma

Pulmonary Pharmacology and Therapeutics

Volumn 27, Issue 1, 2014, Pages 52-56

  Akamatsu, Taisuke ^a   Shirai, Toshihiro ^b   Kato, Masato ^a   Yasui, Hideki ^a   Hashimoto, Dai ^a   Fujisawa, Tomoyuki ^a   Tsuchiya, Tomoyoshi ^c   Inui, Naoki ^a   Suda, Takafumi ^a   Chida, Kingo ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHIZUOKA GENERAL HOSPITAL   (Japan)

^c SHIZUOKA CITY SHIMIZU HOSPITAL   (Japan)

Author keywords

Alveolar nitric oxide; Exhaled nitric oxide; Formoterol budesonide; Salmeterol fluticasone; Switching therapy

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; NITRIC OXIDE;

ADULT; ARTICLE; ASTHMA; ASTHMA CONTROL QUESTIONNAIRE; DISEASE CONTROL; DISEASE SEVERITY; DRUG SUBSTITUTION; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FRACTIONAL EXHALED NITRIC OXIDE; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUESTIONNAIRE; RESPIRATORY TRACT INFLAMMATION; SPIROMETRY; TREATMENT DURATION;

ACQ5; ALVEOLAR NITRIC OXIDE; ALVEOLAR NO CONCENTRATION; ANALYSIS OF VARIANCE; ANOVA; ASTHMA CONTROL QUESTIONNAIRE 5-ITEM VERSION; CANO; EXHALED NITRIC OXIDE; FBC; FEF50%; FENO; FORCED EXPIRATORY FLOW AT 50% OF FVC; FORMOTEROL/BUDESONIDE; FORMOTEROL/BUDESONIDE COMBINATION; FRACTIONAL EXHALED NITRIC OXIDE; GINA; GLOBAL INITIATIVE FOR ASTHMA; ICS; INHALED CORTICOSTEROID; J'AWNO; LABA; LONG-ACTING Β2-AGONIST; LOWEST PEF EXPRESSED AS A PERCENTAGE OF THE HIGHEST PEF; MASS MEDIAN AERODYNAMIC DIAMETERS; MAXIMAL NO FLUX IN THE CONDUCTIVE AIRWAYS; MIN%MAX PEF; MMADS; PEAK EXPIRATORY FLOW; PEF; SABA; SALMETEROL/FLUTICASONE; SALMETEROL/FLUTICASONE COMBINATION; SFC; SHORT-ACTING Β2-AGONIST; SWITCHING THERAPY;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; AGED; ALBUTEROL; ANDROSTADIENES; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NITRIC OXIDE; PROSPECTIVE STUDIES; PULMONARY ALVEOLI; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TREATMENT OUTCOME;

EID: 84892441613     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.04.001     Document Type: Article

References (21)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2012 (available on ). http://www.ginasthma.org.
2. Dahl R., Chuchalin A., Gor D., Yoxall S., Sharma R. EXCEL: a randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma. Respir Med 2006, 100:1152-1162.
3. Kuna P., Peters M.J., Manjra A.I., Jorup C., Naya I.P., Martínez-Jimenez N.E., et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007, 61:725-736.
4. Akamatsu T., Shirai T., Kato M., Hashimoto D., Yasui H., Inui N., et al. Effect of switching from salmeterol/fluticasone to formoterol/budesonide combinations in patients with uncontrolled asthma. Allergol Int 2012, 61:323-329.
5. Tarsin W., Assi K.H., Chrystyn H. In-vitro intra- and inter-inhaler flow rate-dependent dosage emission from a combination of budesonide and eformoterol in a dry powder inhaler. J Aerosol Med 2004, 17:25-32.
6. Granlund K.M., Asking L., Lindblad T., Rollwage U., Steckel H. An in-vitro comparison of budesonide/formoterol and fluticasone/salmeterol in dry powder inhalers. Eur Respir J 2000, 16(Suppl. 31):455s.
7. Johnson J.R., Hamid Q. Appraising the small airways in asthma. Curr Opin Pulm Med 2012, 18:23-28.
8. Tsoukias N.M., George S.C. A two-compartment model of pulmonary nitric oxide exchange dynamics. J Appl Physiol 1998, 85:653-666.
9. Kondo T., Tanigaki T., Kato S., Tazaki G., Watanabe H., Tsunoda T., et al. Flow and inspiratory pressure characteristics of In-Check and training whistles. Arerugi 2012, 61:813-819.
10. Juniper E.F., Svensson K., Mörk A.C., Ståhl E. Measurement properties and interpretation of three shortened versions of the Asthma Control Questionnaire. Respir Med 2005, 99:553-558.
11. The Committee of Pulmonary Physiology, Japanese Respiratory Society Guidelines for pulmonary function tests. spirometry, flow-volume curve, diffusing capacity of the lung 2004, The Japanese Respiratory Society, Tokyo.
12. Reddel H.K., Salome C.M., Peat J.K., Woolcock A.J. Which index of peak expiratory flow is most useful in the management of stable asthmaα. Am J Respir Crit Care Med 1995, 151:1320-1325.
13. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal oxide, 2005. Am J Respir Crit Care Med 2005, 171:912-930.
14. Condorelli P., Shin H.W., Aledia A.S., Silkoff P.E., George S.C. A simple technique to characterize proximal and peripheral nitric oxide exchange using constant fiow exhalations and an axial diffusion model. J Appl Physiol 2007, 102:417-425.
15. Hozawa S., Terada M., Hozawa M. Comparison of budesonide/formoterol Turbuhaler with fluticasone/salmeterol Diskus for treatment effects on small airway impairment and airway inflammation in patients with asthma. Pulm Pharmacol Ther 2011, 24:571-576.
16. American College of Chest Physicians Aerosol consensus statement. Consensus conference on aerosol delivery. Chest 1991, 100:1106-1109.
17. Van Muylem A., Kerckx Y., Michils A. Acinar effect of inhaled steroids evidenced exhaled nitric oxide. J Allergy Clin Immunol 2010, 126:730-735.
18. Gelb A.F., Taylor C.F., Simmons M., Shinar C. Role of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 μg/salmeterol 50 μg. Pulm Pharmacol Ther 2009, 22:516-521.
19. Shin H.W., Schwindt C.D., Aledia A.S., Rose-Gottron C.M., Larson J.K., Newcomb R.L., et al. Exercise-induced bronchoconstriction alters airway nitric oxide exchange in a pattern distinct from spirometry. Am J Physiol Regul Integr Comp Physiol 2006, 291:R1741-R1748.
20. Kerckx Y., Michils A., Van Muylem A. Airway contribution to alveolar nitric oxide in healthy subjects and stable asthma patients. J Appl Physiol 2008, 104:918-924.
21. Prime D., Grant A.C., Slater A.L., Woodhouse R.N. A critical comparison of the dose delivery characteristics of four alternative inhalation devices delivering salbutamol: pressurized metered dose inhaler, Diskus inhaler, Diskhaler inhaler, and Turbuhaler inhaler. J Aerosol Med 1999, 12:75-84.